Company
Anteris Technologies Pty Ltd
ASX:AVR
Anteris Technologies Pty Ltd is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.
133 stories · page 1 of 2
Anteris Technologies boosted by $1.6 million R&D tax incentive refund
The Australian Government’s Research and Development Tax Incentive claim confirms Anteris’ significant and ongoing commitment to invest in, research and develop its structural heart technologies.
Anteris Technologies preliminary results show restoration of pre-disease blood flow compared to competing technologies
When current generation competing valve technologies were compared to the healthy aortic valve, they demonstrated statistically significant worse flow.
Anteris Technologies hosts Australian interventional cardiology experts at 3D tissue design facility in Perth
The company intends to partner with the clinicians to commercialise its DurAVR™ Transcatheter Heart Valve system, as well as to refine its clinical roadmap while also improving investor engagement.
Anteris Technologies' transcatheter heart valve continues to demonstrate its potential
Anteris’ mission is simple: to build a heart valve that lasts longer and works better than existing solutions. Now, with a fully realised product under its wing, the healthcare stock is working towards Food and Drug Administration clearance
Anteris Technologies appoints highly experienced doctor to help accelerate and further validate DurAVR™
New Anteris Global Medical Advisory Board member Dr Martin Leon MD will help accelerate the company's work in heart health treatment.
Anteris Technologies' heart valve technology continues to demonstrate improvement in blood flow and quality-of-life markers
“Its remarkable flow characteristics are as close to a normal human aortic valve as we have seen, a testament to the unique 3D tissue design,” chief medical officer Dr Chris Meduri said.
Anteris Technologies higher as six-month follow up shows 86% improvement in haemodynamics
The six-minute walk test, a key well-being marker, improved 46% since baseline and a further 21% between three and six months, demonstrating how much more active and fit patients can become when implanted with the DurAVR™ valve.
Anteris Technologies completes treatment of second cohort in first-in-human study for transcatheter heart valve system
“We are thrilled with the ongoing progress and the veracity of the results so far. The whole team including the treating physicians are excited by the results so far,” says CEO Wayne Paterson.
Anteris Technologies starts treating second cohort in first in-human study
Anteris Technologies Ltd is now treating its second cohort of patients as part of the first-in-human study for the company’s DurAVR™ transcatheter heart valve system.
Anteris Technologies enhances Australian Medical Advisory Board
Associate Professor Dion Stub of the Alfred Hospital and Monash University specialises in structural heart procedures, including angioplasty, aortic valve replacement (TAVI) and balloon valvuloplasty.
Anteris Technologies in research partnership with Yale University and Yale Cardiovascular Research Group
“This partnership is a testament of Anteris’ commitment to continue to advance valve science through rigorous, scientific research with best-in-class academic centres,” says CEO.
Anteris Technologies welcomes interventional cardiologist Dr Karl Poon to global Medical Advisory Board
Brisbane-based Dr Poon has expertise in structural heart disease interventions and is among Australia's most prolific implanters of transcatheter aortic valve implantation devices.
Anteris Technologies says “no deal” to NASDAQ-lister's merger proposal
“Despite some advantages, such as relatively expeditious access to US capital markets, the company’s board concluded the timing of the proposal was not in shareholders' nor the company’s best interest at this point,” Anteris stated on Tuesd
Anteris Technologies considers proposal to merge with 'blank check' NASDAQ-lister
Last month, Anteris’ first-in-human DurAVR THV (transcatheter heart valve) study met or exceeded its interim study objectives, with patients reporting 'impressive' haemodynamic improvement.
Anteris Technologies' first-in-human DurAVR™ THV study meets or exceeds interim study objectives
The company plans to continue the study with the next cohort, as well as recruit patients for its US FDA investigational device exemption (IDE) study.
Anteris Technologies strengthens IP portfolio with new patent application for ADAPT®
The proven benefits of its patented ADAPT® tissue technology, paired with the unique design of its DurAVR™ 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and
Anteris Technologies boosts finances by almost A$19 million through exercising options
Total gross proceeds from the exercising of 2,370,209 listed options that were on issue on November 1, 2021, and expired on December 18, 2021, was $18,961,672.
Anteris Technologies buoyed by follow-up milestone from first-in-human DurAVR™ heart valve study
When the ASX-lister checked in with the study’s patients seven days after their procedure, all were responding in line with clinical expectations.
Anteris Technologies’ DurAVR heart valve tech featured at major medical conference
“With our first-in-human study now underway, we anticipate even more profile for the company in 2022 at the major medical conferences,” says CEO.
Anteris Technologies successfully implants five heart patients with valve technology
The 'first to human' transcatheter aortic valve replacement procedures for all five patients were successful and proceeded without any complications.
Anteris Technologies’ heart technology on the pulse at London conference
The company has been invited to present life-saving heart valve technology in the innovation sessions at an international heart valve conference in London.
Anteris Technologies raises $5 million to develop aortic replacement valve
“As the company is rapidly approaching its first in human studies we are very pleased to welcome L1 onto our share register,” Anteris CEO Wayne Paterson said.
Anteris Technologies accepted into innovation session at prestigious Interventional cardiology meeting
“The innovation sessions are keenly observed by physicians, analysts and senior industry executives. The potential of this product to fill the treatment gap for younger patients needing longer lasting and better working valves is being reco
Anteris Technologies partners with medtech heavyweights for FDA early feasibility study
IQVIA and CRF have vast experience in this space and complement AVR’s development of next-generation technologies including the Anteris DurAVR™ aortic replacement valve.
Anteris Technologies completes crucial final animal study ahead of heart valve replacement clinical trial
Formal results from a three-month study of Anteris’ DurAVR™ heart valve replacement in six sheep will be available in the next month.
Anteris Technologies appoints highly experienced chief medical officer
The appointment of Dr Meduri, a recognised leader in the field of valvular heart disease, is expected to give further credibility to Anteris’ DurAVR™ aortic replacement valve.
Anteris Technologies extends manufacturing agreement with LeMaitre for CardioCel™ and VascuCel™
Anteris Technologies is a structural heart company delivering clinically superior and durable solutions through better science and better design.
Anteris Technologies raises $9 million by issuing placement shares to sophisticated investors
CEO Paterson said: “With this new capital round we will continue to deliver on our plan of achieving EFS approval in 2021 as well as advancing our Coronary Artery Bypass Graft and surgical valve projects.”